ImmuneOnco IMM2510 Combined with Chemotherapy for First-Line NSCLC Treatment Completes Enrollment of First Patient in Phase Ib/II Clinical Trial-宜明昂科英文

Company News

Home Company News News detail

ImmuneOnco IMM2510 Combined with Chemotherapy for First-Line NSCLC Treatment Completes Enrollment of First Patient in Phase Ib/II Clinical Trial

2025-01-13

2035

Previous article：Approval by the NMPA for Clinical Trial of IMM01 (timdarpacept) Combined with IMM2510 (palverafusp α) and with or without Chemotherapy for Advanced Malignant Tumors

Next article：The Phase II clinical trial of IMM27M for estrogen receptor positive (ER+) advanced breast cancer that failed after endocrine therapy or recurred and has enrolled the first patient

Hot recommendation

ImmuneOnco Successfully Convenes Phase II Investigator Meeting for IMC-002 (IMM0306) in Active Systemic Lupus Erythematosus (SLE)

IMM2510S，the Subcutaneous Formulation of IMM2510 Completes First Patient Dosing in Phase I Clinical Study, Ushering in a New Era of Convenient Dual-Target Therapy

ImmuneOnco Completes planned Enrollment of 173 Patients in Phase III Registrational Trial of Timdarpacept (IMM01) for CMML

For more information

Please follow the official wechat public account